Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (116)	11/10/2003 6:53:43 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 411

Is this CVTX compound? Maybe they have different opinion on trial success, so they left it unreported? Miljenko PS:<<In addition, the study showed increases in sodium excretion above baseline and above placebo beginning on Day 1, and continuing over the 10-day dosing period. These effects were not accompanied by reductions in kidney function or substantial increases in potassium excretion.>> No single number, so data must be very good (bad).